Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

NCT05533008 is registered in ClinicalTrials.gov with Cara Therapeutics, Inc. as lead sponsor.

NCT NCT05533008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05533008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients
Lead sponsor
Cara Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2019
Completion date
June 11, 2020
Enrollment
35 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis